Rapid Communication

Changes in treatment adherence and behaviour during the COVID-19 pandemic in Japanese patients with rheumatoid arthritis: results from cross-sectional study in the IORRA cohort

Eiichi Tanaka a, b, Eisuke Inoue a, c, Mai Abe a, b, Kumiko Saka a, b, Eri Sugano a, b, Moeko Ochiai a, b, Rei Yamaguchi a, b, Katsunori Ikari h, d, e, Hisashi Yamanaka a, f, g, Masayoshi Harigai a, b

a Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
b Institute of Rheumatology, Tokyo Women’s Medical University Hospital, Tokyo, Japan
c Research Administration Center, Showa University, Tokyo, Japan
d Division of Multidisciplinary Management of Rheumatic Diseases, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
e Department of Orthopedic Surgery, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
f Rheumatology, Sanno Medical Center, Tokyo, Japan
g Department of Rheumatology, International University of Health and Welfare, Tokyo, Japan

Numbers of text pages: 7, Numbers of table: 1 table

Key words: COVID-19, pandemic, adherence, methotrexate, biological disease-modifying antirheumatic drugs, rheumatoid arthritis

Corresponding author: Eiichi Tanaka,
Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Phone: 81-3-3353-8111, Fax: 81-3-5269-1725, E-mail: e-tanaka@twmu.ac.jp, ORCiD iD: 0000-0003-2850-326X

© Japan College of Rheumatology 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
During the coronavirus disease 2019 (COVID-19) pandemic, the behaviour and adherence to medications in patients with rheumatic diseases have become major concerns. The American College of Rheumatology guidance (1) and European League Against Rheumatic Diseases recommendation (2) indicated that medical treatment of patients with rheumatic diseases should be continued during the COVID-19 pandemic when COVID-19 infection is not suspected. The Japan College of Rheumatology also announced that patients with rheumatic diseases should continue currently prescribed medications such as immunosuppressants, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs), and corticosteroids at the same dose, and not discontinue these medications using self-judgment, to prevent worsening of symptoms of rheumatic diseases (3). Studies from Greece (4), Germany (5), Mexico (6), Denmark (7), and Saudi Arabia (8) reported high adherence to medications in patients with rheumatoid arthritis (RA) during the COVID-19 pandemic. In Japan, > 1.7 million people were infected with the severe acute respiratory syndrome coronavirus 2, and > 18,000 people have died as of October 2021, but there are no large-scale studies on this issue, including the status of COVID-19 infection in patients with RA in Japan. Therefore, we conducted a cross-sectional study using the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) survey on the treatment adherence and behaviour of Japanese patients with RA during the COVID-19 pandemic.

The IORRA survey, a prospective, large, single-institute-based observational cohort study of patients with RA, is being conducted since 2000 at the Tokyo Women’s Medical University (9). To briefly explain the IORRA cohort, all Japanese patients with RA who visit our hospital are registered in the IORRA cohort. Data are collected biannually, including patients’ self-assessment, physician assessment, and laboratory data. Data have been accumulated for 21 years. The IORRA study was approved by the Ethics Committee of Tokyo Women’s Medical University School of Medicine (No. 2922-R16), and informed consent was obtained from the patients at study entry and each survey.

In the IORRA survey conducted from October to December 2020, adherence to RA medications and self-reported changes in RA disease activity, behaviour including frequency of hospital visits, and COVID-19 infection status during the COVID-19 pandemic were cross-sectionally investigated. This information was obtained from the patients’ self-reported response. Of the 2,996 RA patients who participated in this survey, 2,785 (93.0%) continued to use RA medications as usual. Similar to previous reports from around the world (4-8), adherence to RA medications was shown to be high in Japanese patients with RA. RA medications were reduced in 96 (3.2%) patients (interval extension, 47 patients; dose reduction, 50 patients), and were discontinued in 89 (3.0%) patients. Of the 89 patients who discontinued RA medications, the number of patients...
who discontinued DMARDs was as follows: methotrexate (MTX) 47 (52.8%); immunosuppressants other than MTX, such as tacrolimus and leflunomide 11 (12.4%); immunomodulators such as salazosulfapyridine, bucillamine, and iguratimod 7 (7.9%); molecular targeted drugs such as bDMARDs and Janus kinase inhibitor 27 (30.3%), and corticosteroids 10 (11.2%). Thus, MTX and bDMARDs were more frequently discontinued, which might reflect high proportion of MTX (72.0%) and bDMARDs (32.8%) users in the whole group in this survey (note that these percentage were same as those of the patients without COVID-19). The most common reason for reducing or discontinuing RA medications (n = 185) was “My doctor and I made a decision together” (53.5%), followed by “I made a decision by myself” (43.8%) and “I followed advice from my family members and friends” (1.1%). Among 185 patients who reduced or discontinued RA medications, the proportion of patients whose self-reported RA activity A: did not worsen; B: worsened, and RA medications were returned to usual dosages; and C: worsened, but RA medications remained reduced or discontinued was A: 63.8%, B: 26.5%, and C: 3.8%. Approximately one-third of the patients experienced worsening of RA disease activity due to reduction in or discontinuation of RA medications.

Regarding the frequency of hospital visits (n= 2,996), the proportion of patients with RA who visited our clinic as usual, visited our clinic at a longer interval than usual, consulted a doctor over telephone, and were transferred to nearby hospitals or clinics was 70.4%, 23.1%, 11.8%, and 0.8%, respectively. During the COVID-19 pandemic, remote medical-care strategies, rather than face-to-face consultations, might be useful in patients with rheumatic diseases who are prescribed immunosuppressive medications, as reported in Switzerland (10) and Egypt (11).

Among 2,996 RA patients who participated in this survey, 46 and 2,915 RA patients self-reported that they had been diagnosed with and without COVID-19 until September 2020, respectively. We did not ask how RA patients were diagnosed with COVID-19 in the questionnaire. Table 1 shows the differences in characteristics between patients with RA with (n = 46) and without (n = 2,915) self-reported COVID-19. Patients with COVID-19 were young, had low disease activity, and had good physical function, suggesting that these patients seemed to have good activity of daily living; however, no specific tendency was observed with regard to the RA medication used. In addition, of the 46 RA patients with COVID-19, source of infection was confirmed in only one patient. The symptoms of COVID-19 were fever in two (4.3%) patients, and cough, dyspnoea or shortness of breath, hypogeusia, and hyposmia in one (2.2%) patient each; no patient with RA presented with pneumonia or required hospitalization. Several reports have described COVID-19 in patients with rheumatic diseases (12, 13). Of the 47 patients with COVID-19 with rheumatic diseases in Saudi Arabia, 48.9% required
hospitalisation, and elderly patients with a mean age of 65 years had an increased risk of hospitalisation and development of severe COVID-19 pneumonia (12). Corticosteroid use > 10 mg/day was significantly associated with an increased risk, and tumour necrosis factor inhibitor use was associated with a decreased risk of hospitalisation in 600 patients with COVID-19 with rheumatic diseases from 40 countries (13). It is expected that the accumulation of data of Japanese patients with COVID-19 with rheumatic diseases will clarify which patients are susceptible to COVID-19, how we should modify RA medications in patients with RA with COVID-19, and the risk of severe COVID-19 in Japan.

The strength of this study was that a large population of patients with RA was analysed using real-world data. However, a limitation of this study was that the IORRA cohort study is a single-centre study and our hospital is located at the centre of Tokyo, which may limit the generalizability of the results.

In conclusion, most (93.0%) Japanese patients with RA continued to use RA medications as usual, and adherence to RA medications was high during the COVID-19 pandemic. Some patients reduced or discontinued RA medications such as MTX and bDMARDs, resulting in approximately one-third of the patients experiencing worsening of self-reported RA disease activity. Patients with RA with COVID-19 had good activities of daily living; however, no specific tendency was observed with regard to the RA medication used.

Acknowledgments

We thank all the members of the Institute of Rheumatology, Tokyo Women’s Medical University Hospital for the successful management of the IORRA study cohort. We would also like to thank the following pharmaceutical companies for providing unrestricted grants to support the IORRA database: Asahi Kasei Pharma Co.; Astellas Pharma Inc.; AbbVie Japan GK; Ayumi Pharmaceutical Co.; Eisai Co., Ltd.; Kaken Pharmaceutical Co., Ltd.; Kissei Pharmaceutical Co., Ltd.; Sekisui Medical Co., Ltd.; Taisho Pharma Co., Ltd.; Daiichi-Sankyo Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Chugai Pharmaceutical Co., Ltd.; Teijin Pharma Ltd.; Nippon Shinyaku Co., Ltd.; Nippon Kayaku Co., Ltd.; Pfizer Japan Inc.; Bristol Myers Squibb; Mochida Pharmaceutical Co., Ltd.; and UCB Japan Co. Ltd. We would like to thank Editage (www.editage.com) for English language editing.

Conflict of interest

ET has received lecture fees or consulting fees from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K.,
GlaxoSmithKline K.K., Kyowa Pharma Chemical CO., Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical CO., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. EI has received speaker fee from Bristol Myers Squibb Co., Ltd. and Pfizer Japan Inc. KI has received speaker fees from Asahi Kasei Corp.; Astellas Pharma Inc.; AbbVie Japan GK; Ayumi Pharmaceutical Co.; Bristol Myers Squibb Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Eli Lilly Japan K.K.; Janssen Pharmaceutical K.K.; Kaken Pharmaceutical Co. Ltd.; Mitsubishi Tanabe Pharma Co.; Pfizer Japan Inc.; Takeda Pharmaceutical Co. Ltd.; Teijin Pharma Ltd.; and UCB Japan Co. Ltd. Division of Multidisciplinary Management of Rheumatic Diseases is an endowment department, supported by an unrestricted grant from Ayumi Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Mochida Pharmaceutical Co., Ltd.; Nippon Kayaku Co., Ltd.; and Teijin Pharma Ltd. HY has received speaker or consulting fees from Teijin Pharma Ltd, and YL Biologics Ltd. MH has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekisui Medical, Shionogi & Co., Ltd.; Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. MH is a consultant for AbbVie Japan GK, Boehringer-Ingelheim, Bristol Myers Squibb Co., Ltd., Kissei Pharmaceutical Co., Ltd. and Teijin Pharma Ltd. MH has received speaker’s fee from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer-Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. The other authors declare no conflicts of interest on this study.

Funding
This work was supported by Health and Labour Sciences Research Grants for Research on Allergic Disease and Immunology from the Ministry of Health, Labour and Welfare (grant number H30-Meneki-Shitei-002) and Japan Agency for Medical Research and Development (grant number 21ek0410086h0001).

References
1. Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. Arthritis Rheumatol. 2021;73(2):e1-e12.
2. Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851-8.

3. https://www.ryumachi-jp.com/information/medical/covid-19_2/

4. Fragoulis GE, Evangelatos G, Arida A, Bournia VK, Fragiadaki K, Karamanakos A, et al. Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. Ann Rheum Dis. 2020 May 31:annrheumdis-2020-217935. doi: 10.1136/annrheumdis-2020-217935. Online ahead of print.

5. Hasseli R, Müller-Ladner U, Keil F, Broll M, Dormann A, Fräbel C, et al. The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication - a cross-sectional study over 3 months in Germany. Rheumatology (Oxford). 2021 Mar 11:keab230. doi: 10.1093/rheumatology/keab230. Online ahead of print.

6. Pineda-Sic RA, Galarza-Delgado DA, Serna-Peña G, Castillo-Torres SA, Flores-Alvarado DE, Esquivel-Valerio JA, et al. Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience. Ann Rheum Dis. 2020 Jun 23:annrheumdis-2020-218198. doi: 10.1136/annrheumdis-2020-218198. Online ahead of print.

7. Glintborg B, Jensen DV, Engel S, Terslev L, Pfeiffer Jensen M, Hendricks O, et al. Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12,000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry. RMD Open. 2021;7(1):e001505.

8. Hassen LM, Almaghlouth IA, Hassen IM, Daghestani MH, Almohisen AA, Alqurtas EM, et al. Impact of COVID-19 outbreak on rheumatic patients' perceptions and behaviors: A cross-sectional study. Int J Rheum Dis. 2020;23(11):1541-9.

9. Yamanaka H, Tanaka E, Nakajima A, Furuya T, Ikari K, Taniguchi A, et al. A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today's treatment options. Mod Rheumatol. 2020;30(1):1-6.

10. Ciurea A, Papagiannoulis E, Bürki K, von Loga I, Micheroli R, Möller B, et al. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2021;80(2):238-41.

11. Abualfadl E, Ismail F, Shereef RRE, Hassan E, Tharwat S, Mohamed EF, et al.; ECR COVID19-Study Group. Impact of COVID-19 pandemic on rheumatoid arthritis from a Multi-Centre patient-reported
questionnaire survey: influence of gender, rural-urban gap and north-south gradient. Rheumatol Int. 2021;41(2):345-53.

12. Alzahrani ZA, Alghamdi KA, Almaqati AS. Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases. Rheumatol Int. 2021;41(6):1097-103.

13. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-66.
|                      | RA patients with COVID-19 (n=46) | RA patients without COVID-19 (n=2,915) | P-value |
|----------------------|----------------------------------|----------------------------------------|---------|
| Female               | 37 (80.4)                        | 2543 (87.2)                            | 0.26    |
| Age, years*          | 51.8 (42.1−62.3)                 | 64.3 (53.2−72.6)                       | < 0.01  |
| Disease duration, years | 13 (10−20)                        | 16 (10−24)                             | 0.08    |
| BMI, mg/m²           | 21.0 (19.8−25.5)                 | 21.2 (19.2−23.3)                       | 0.08    |
| DAS28-ESR*           | 1.8 (1.3−2.2)                    | 2.3 (1.7−3.0)                          | < 0.01  |
| CDAI*                | 2.0 (0.8−5.5)                    | 2.7 (0.8−6.1)                          | 0.02    |
| SDAI*                | 2.0 (1.0−5.7)                    | 3.0 (1.0−6.5)                          | < 0.01  |
| EQ-5D*               | 0.90 (0.79−1.0)                  | 0.89 (0.76−1.0)                        | 0.05    |
| J-HAQ*               | 0 (0−0.34)                       | 0.25 (0−1.0)                           | < 0.01  |
| RF positive          | 20 (55.6)                        | 1744 (79.2)                            | < 0.01  |
| ACPA positive        | 32 (80.0)                        | 2203 (82.5)                            | 0.70    |
| Medication           |                                  |                                       |         |
| NSAIDs use           | 22 (47.8)                        | 1340 (46.0)                            | 0.81    |
| Corticosteroid use   | 7 (15.2)                         | 655 (22.5)                             | 0.19    |
| Corticosteroid dose, mg/day | 5.0 (2.5−6.5)                  | 3.0 (2.0−5.0)                          | 0.32    |
| csDMARDs use         | 42 (91.3)                        | 2500 (85.8)                            | 0.20    |
| MTX use              | 35 (76.1)                        | 2098 (72.0)                            | 0.52    |
| MTX dose, mg/week    | 8.4 (6.4−10.0)                   | 8.0 (6.0−10.0)                         | 0.95    |
| BUC use              | 3 (6.5)                          | 177 (6.1)                              | 0.90    |
| SASP use             | 7 (15.2)                         | 467 (16.0)                             | 0.88    |
| TAC use              | 1 (2.2)                          | 129 (4.4)                              | 0.31    |
| IGU use              | 5 (10.9)                         | 272 (9.3)                              | 0.74    |
| bDMARDs use          | 17 (37.0)                        | 957 (32.8)                             | 0.57    |
| TNF inhibitor use    | 8 (17.4)                         | 506 (17.4)                             | 0.99    |
| Non-TNF inhibitor use| 9 (19.6)                         | 461 (15.8)                             | 0.53    |
| JAK inhibitor use    | 1 (2.2)                          | 47 (1.6)                               | 0.80    |

Continuous variables are summarised as medians with interquartile ranges (IQRs). Categorical variables are presented as number (%). For descriptive purposes, group differences were evaluated using the Wilcoxon rank-sum test and Fisher’s exact test for continuous and categorical variables, respectively.

* Statistically significant differences between RA patients with and without COVID-19 (p<0.05).

ACPA: anti-cyclic citrullinated peptide antibody, bDMARDs: biological DMARDs, BMI: body mass index, BUC: bucillamine, CDAI: Clinical Disease Activity Index, csDMARDs: conventional synthetic DMARDs, DAS28-ESR: disease activity score 28-joint count using erythrocyte sedimentation rate, DMARDs: disease-modifying anti-rheumatic drugs, EQ-5D: EuroQoL 5 Dimension, IGU: iguratimod, IQR: interquartile range, JAK: Janus kinase, J-HAQ: Japanese version of health assessment questionnaire, MTX: methotrexate, NSAID: non-steroidal anti-inflammatory drug, RA: rheumatoid arthritis, RF: rheumatoid factor, SASP: salazosulfapyridine, SDAI: simplified disease activity index, TAC: tacrolimus, TNF: tumour necrosis factor.